Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Material Litigation
confidence 85%
filed 2026-07-09
Item 8.01
The filing discloses material stockholder litigation and threatened litigation related to the pending merger. Two complaints were filed in New York state court on June 24, 2026 alleging negligent misrepresentation and concealment regarding proxy statement disclosures, and eleven demand letters threatening litigation were received between April 29 and July 1, 2026. Additionally, a Delaware Section 220 demand for inspection of books and records was received on July 8, 2026. Although the company denies liability and made supplemental disclosures to avoid litigation delays, the existence of actual filed complaints and multiple threatened actions constitutes material litigation disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-09
Item 3.01
Prairie received a Nasdaq Minimum Bid Price Notice on July 2, 2026, indicating that its common stock closing bid price has been below the required $1.00 per share for 30 consecutive business days. The company has been granted an initial 180-day compliance period (until December 29, 2026) to regain compliance, with potential delisting consequences if it fails. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-07-09
EX-99.1
This is a press release announcing Q2 2026 gold production results (176,836 ounces) and year-to-date production (374,464 oz), with guidance confirmation for full-year 2026 production of 700,000–800,000 oz. The release discloses operational metrics and production performance across multiple mines, which are core financial and operational results material to investors assessing the registrant's performance and ability to meet guidance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-07-09
EX-99.1
This is an announcement of an upcoming earnings release and conference call for Q2 2026 results scheduled for August 12–13, 2026. While the actual financial results are not disclosed in this exhibit, the press release announces the timing and logistics of the earnings announcement, which is a standard precursor to an earnings event. The disclosure identifies the CEO and CFO who will discuss performance, making it material to investors planning to access the results.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-09
Item 2.02
NTIC disclosed consolidated financial results for the third fiscal quarter ended May 31, 2026, via a press release attached as Exhibit 99.1. The disclosure includes quarterly net sales ($24.2M, up 12.6%), gross profit margins (down 477 basis points), and net loss per diluted share ($0.03 vs. prior year income of $0.01). This is a standard quarterly earnings release material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-09
EX-99.1
Anfield announced a Mining Lease Agreement dated July 1, 2026, with Gold Eagle Mining Inc. for two additional patented mining claims in Colorado (Slick Rock Claim and Paradox D Claim). The lease expands the company's land holdings for the JD-5 and Slick Rock projects and will be integrated into mine design and permitting activities. This is a material operational/strategic event involving acquisition of mining rights that supports the company's hub-and-spoke uranium-vanadium development strategy, though it does not constitute a traditional M&A transaction (acquisition of a company or material asset sale/purchase) and is better classified as an operational expansion.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-09
EX-99.1
The press release announces the issuance of approximately 15.7 million new warrants (New EIB Warrants) to the European Investment Bank at €0.01 per warrant, representing approximately 6.5% of the Company's current share capital on a non-diluted basis. This is a dilutive equity issuance that would materially affect shareholder ownership and voting rights. The transaction is part of a broader refinancing and capital structure optimization, and the warrants are exercisable from August 30, 2026 through January 4, 2036, creating future dilution potential.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-07-09
EX-99.1
This press release announces completion of Phase 2 of a three-phase Option Agreement with Denison Mines, whereby Foremost increases its ownership interest from 20% to 51% across 10 Athabasca uranium projects (35.78% at Hatchet Lake). The transaction involves issuance of 848,610 shares valued at $2 million and completion of $8 million in exploration expenditures, representing a material change in Foremost's ownership and control of significant mineral assets. This constitutes a material acquisition or change of control event under the ma_activity category.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-09
EX-99.1
CAE announces a voluntary transfer of its U.S. stock exchange listing from the NYSE to the Nasdaq Global Select Market, effective July 23, 2026. While this is a voluntary transfer rather than an involuntary delisting, it constitutes a material change in listing venue that affects where and how the company's shares trade in the U.S. market. The disclosure explicitly states the last trading day on NYSE (July 22, 2026) and commencement on Nasdaq (July 23, 2026), making this a transfer of listing under Item 3.01 framework, which is material to investors' ability to trade the security.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-07-09
The 8-K discloses fiscal 2027 first quarter financial results via press release (Item 2.02), with detailed financial metrics including net revenues of $4.8 million (down from $7.1 million), net loss of $(1.4) million, and loss per share of $(0.16). The filing explicitly states the company "announced, via press release, fiscal 2027 first quarter financial results" and includes the full press release as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-07-09
NaaS Technology Inc. entered into a definitive Share Acquisition Agreement on July 9, 2026, to acquire 100% of the issued and outstanding shares of China Newlink Holding Limited for US$15,000,000 in newly issued Class A ordinary shares. This constitutes a material acquisition transaction requiring disclosure under Item 1.01 of Form 8-K (or equivalent 6-K disclosure). The transaction is binding, involves a substantial equity issuance (16 billion Class A shares / 5 million ADSs), and is subject to customary closing conditions including regulatory approvals and Audit Committee review.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-09
Item 1.01
The filing discloses entry into a material definitive agreement—an amendment to an existing Loan and Security Agreement with Oxford Finance LLC that modifies the terms and availability of a $150 million non-dilutive term loan facility. The amendment extends the availability of the remaining $15 million of Term A Loans through December 31, 2026, and conditionally extends the availability of Term B and Term C Loans, along with modifications to revenue covenants and non-utilization fees. This is a material modification to the Company's direct financial obligations and capital structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-09
EX-99.1
Virax Biolabs announced an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering six Southeast Asian markets for its ImmuneSelect product line. This is a material strategic partnership and commercial milestone that establishes a framework for immediate product supply and revenue opportunities, representing a significant operational and commercial development for the company's business expansion in the ASEAN region.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-09
Item 5.02
The filing discloses the appointment of Nancy Bowman, M.D., Ph.D., as Chief Regulatory Officer effective August 3, 2026, succeeding William Turner. While Turner's transition to Special Advisor represents a departure from his CRO role, the principal disclosed action centers on the appointment of a new CRO—a material executive officer position at a therapeutic company where regulatory affairs are critical to operations and strategy.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-09
Item 7.01
Forte Biosciences issued a press release on July 9, 2026 announcing positive Phase 1b clinical trial results for FB102 in vitiligo, including statistically significant efficacy endpoints (29.6% mean FVASI improvement, p=0.020) and safety data through week 24 post-treatment.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-09
Item 2.02
The filing discloses a press release announcing year-to-date customer order activity through June 30, 2026, showing a significant 32% increase to approximately $268 million compared to $204 million in the prior-year period. This is a quantitative disclosure of operational and financial performance metrics for the first half of 2026, which is the hallmark of an earnings or results announcement under Item 2.02. While technically reporting "order activity" rather than completed earnings, this represents material financial condition disclosure that would affect a reasonable investor's assessment of the company's performance trajectory.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 92%
filed 2026-07-09
EX-99.1
This press release announces the final results of exchange offers whereby Shell Finance US exchanged $6.298 billion in aggregate principal amount of unregistered restricted notes for newly registered exchange notes. While technically an exchange rather than a new issuance, the creation of new registered debt obligations and the material principal amount involved ($6.3 billion across six note series with maturities from 2028 to 2051) constitutes a material debt transaction. The disclosure of the specific series, amounts tendered, and settlement date (July 13, 2026) aligns with Item 2.03 debt issuance disclosure requirements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-09
Item 5.02
FibroBiologics appointed Kathleen Rubins, Ph.D., a retired NASA astronaut and microbiologist, as a Class III director effective July 8, 2026, with assignment to the Audit, Compensation, and Governance committees. Dr. Rubins brings distinguished scientific credentials and has served on the company's Scientific Advisory Board since 2022.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-09
Item 1.01
The Fourth Amendment modifies an existing Revolving Credit Facility by extending the revolving period to July 2, 2028 and stated maturity to July 2, 2030, reducing interest rates (from SOFR+2.35% to SOFR+1.95% during revolving period), and adjusting financial covenants and concentration limits. While this is technically an amendment to existing debt rather than a new issuance, it materially restructures the Company's direct financial obligations and credit terms, which is reportable under Item 1.01 as a material definitive agreement. The extension of maturity dates and reduction in borrowing costs are material to investors assessing the registrant's capital structure and financial flexibility.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-09
Item 5.02
Paul Grewal's departure as Chief Legal Officer and Secretary effective July 31, 2026 is the principal disclosed action. While the filing also mentions Molly Abraham's appointment as General Counsel and an advisor agreement with severance-like terms, the core event centers on Grewal stepping down from a senior officer role. This is material to investors as it affects the registrant's leadership and legal function.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-09
Item 2.01
IKS Health completed its acquisition of TruBridge, Inc., with TruBridge now operating as a wholly owned subsidiary. All shares of Company Common Stock were cancelled and converted into merger consideration, and TruBridge's Common Stock ceased trading on NASDAQ on July 9, 2026.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-09
Item 5.02
The filing discloses the termination of Robert J. Willette as Chief Executive Officer effective April 20, 2026, with a Separation Agreement finalized July 8, 2026. While the disclosure includes compensatory details (cash payment of $1,800,000 and 300,000 stock options), the principal event is the departure of the CEO. The termination was without cause and involved no disagreement with the Company, and the filing centers on the departure itself rather than on compensation arrangement modifications.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
Paycom appointed two directors to its board effective July 8, 2026: Craig E. Boelte, former CFO (retired February 2025), and William Kerber, former CIO (departed 2017). Both individuals bring substantial company history and expertise to the board.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-07-09
Item 5.07
Whitestone REIT shareholders voted on and approved an all-cash acquisition by Ares Real Estate funds at $19.00 per share (approximately $1.7 billion transaction) at a special meeting held on July 9, 2026. The merger proposal received 37,039,161 votes in favor versus 116,016 against and 86,516 abstentions; an advisory say-on-pay proposal failed to achieve majority support. The transaction is expected to close on July 14, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-09
Item 1.01
Morgan Stanley Direct Lending Fund entered into a Fourth Supplemental Indenture on July 9, 2026, to issue $350.0 million aggregate principal amount of 6.100% notes due 2031, with net proceeds of approximately $341.6 million used to repay existing secured indebtedness.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-09
Item 8.01
Blue Owl Technology Income Corp. voluntarily reduced its aggregate committed debt capacity from an undisclosed prior level to $3.5 billion across multiple SPV asset facilities and other credit arrangements on July 2, 2026, in order to reduce borrowing costs and align with target leverage. While this is a financial event involving debt facilities, it does not fit the specific categories of debt_issuance (creation of new obligations), covenant_breach (violation of existing terms), or dividend_distribution. The reduction is a strategic capital structure adjustment that affects the company's financial flexibility and leverage profile, making it material to investors assessing the registrant's financial position and strategy.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-07-09
Item 7.01
The filing discloses the declaration and payment of a quarterly dividend on the Company's 9.50% Series A Cumulative Redeemable Preferred Stock, with a dividend of $0.73889 per share payable on July 31, 2026. This is a routine but material dividend distribution to preferred shareholders, authorized by the Board of Directors and disclosed under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-09
Item 5.02
The disclosure centers on compensatory arrangements approved by the Human Capital and Compensation Committee for Laura Cockrill following her appointment as CFO. The material elements are: base salary increase to $650,000, Annual Bonus Plan target increase to 175% of base salary, LTI target increase to 300% of base salary, and a $1,000,000 retention bonus paid in three tranches through 2029. While the section mentions her prior appointment as CFO (which occurred June 22, 2026 and was previously reported), the substantive new disclosure here is the compensation adjustment and retention bonus arrangement, making this an exec_compensation event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-09
Item 1.01
Interactive Strength Inc. entered into a definitive Stock Purchase Agreement on July 7, 2026 to acquire 100% of STEPR, Inc., a connected stair-climbing fitness equipment company, for total consideration of approximately $19 million in cash, debt, and contingent equity. The transaction is expected to close in Q4 2026 and advances the Company's multi-brand fitness platform strategy, with pro forma revenue guidance exceeding $50 million.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-09
Item 5.07
This is a clear disclosure of shareholder vote results from Netskope's 2026 annual meeting held on July 7, 2026. The filing reports voting outcomes on two proposals: (1) election of Class I directors Sanjay Beri and Arif Janmohamed, and (2) ratification of KPMG LLP as independent auditor. The detailed vote tallies (votes for, against, withheld, and broker non-votes) are the hallmark of Item 5.07 shareholder vote results disclosures, which are material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-07-09
EX-99.1
This announcement discloses a Share Purchase Plan (SPP) — an equity offering to shareholders — with an updated timetable following ASX waiver approvals. SPPs are a form of direct equity issuance that dilutes existing shareholders. The announcement confirms the Company has received waivers from ASX Listing Rules 7.1 and 10.11 and provides revised closing and allotment dates, indicating a material capital-raising activity that would affect investor assessment of share dilution and capital structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-09
The filing discloses that ENDRA regained compliance with Nasdaq's Minimum Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)) after initially falling below the $2,500,000 threshold. However, the company is now subject to a one-year Discretionary Panel Monitor period, during which any future non-compliance with Nasdaq Listing Rules will result in immediate delisting without opportunity for a cure period or compliance plan. This represents a material delisting risk that would significantly affect investor assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-07-09
Item 4.01
The filing discloses the dismissal of Fortune CPA Inc. as the Company's independent registered public accounting firm effective July 6, 2026, and the simultaneous appointment of Wei, Wei & Co., LLP as the successor auditor. While both a departure and appointment occurred, the central event is the auditor change itself. The disclosure notes a material weakness in internal control over financial reporting relating to insufficient staff with appropriate GAAP and SEC reporting knowledge, which contextualizes the change. This is a classic Item 4.01 auditor change disclosure and is material to investors assessing the registrant's financial reporting quality and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-09
EX-99.1
The press release announces the appointment of Ralph (Cody) Kittle to Telesat's Board of Directors as a nominee of MHR Fund Management LLC, succeeding Michael Targoff. This is a discrete governance event involving the appointment of a director to the board. While the release also acknowledges Targoff's departure after 19 years, the principal disclosed action is Kittle's appointment to the board, making this an exec_appointment event. Board composition changes at public companies are material to investors assessing governance and oversight.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-09
EX-99.1
Blue Gold has disclosed that it is at risk of delisting from Nasdaq due to failure to meet continued listing requirements, specifically shareholders' equity requirements. The company has undertaken remedial initiatives including balance sheet optimization, shareholder authorization for a reverse split, and potential transfer to Nasdaq Capital Market.
View raw filing on EDGAR →
6-K
Financial Other
confidence 85%
filed 2026-07-09
EX-99.2
Blue Gold settled US$3.6 million in accounts payable owed by its Ghanaian subsidiary to FGR through conversion into 3,617 shares of Series A Perpetual Convertible Preferred Stock, subject to a 19.99% Nasdaq conversion cap. This material debt-to-equity conversion and liability settlement represents a significant capital restructuring and release of contingent liabilities related to the Bogoso-Prestea mine acquisition.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-07-09
EX-99.1
The press release announces an interim cash dividend of USD 1.50 per ordinary share with specific payment dates (July 27, 2026 for NASDAQ shareholders, July 20, 2026 for JSE shareholders). The disclosure includes ex-dividend dates, record dates, and detailed tax and currency conversion information for South African resident shareholders, which are hallmarks of a dividend distribution announcement.
View raw filing on EDGAR →
6-K
M&A activity
confidence 75%
filed 2026-07-09
EX-99.1
Ambipar executed a Restructuring Support Agreement with creditors holding a majority stake of Green Notes and an Amended and Restated Loan Agreement with Itaú BBA, representing material debt restructuring transactions that significantly alter the registrant's capital structure and financial obligations.
View raw filing on EDGAR →
6-K
Other material
confidence 75%
filed 2026-07-09
EX-99.2
Ambipar disclosed a comprehensive business update and financial condition assessment following its September 2025 pre-injunction filing in Brazil and October 2025 Chapter 11 filing in the U.S., detailing material operational impacts including approximately BRL 800 million backlog reduction, contract cancellations, client attrition, and expected revenue contraction for 2026.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-07-09
EX-99.1
The Company amended a securities purchase agreement and convertible promissory note with Welle Environmental, revising anti-dilution provisions to establish a US$1.30 per-share floor price for equity and convertible securities issuances, with limited exceptions. This amendment reflects negotiation of dilution protections for the investor and indicates an underlying dilutive equity or convertible issuance transaction that materially affects shareholder interests.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-09
Item 8.01
byNordic Acquisition Corp disclosed the extension of its business combination deadline from July 12, 2026 to August 12, 2026 by depositing $17,470 into its trust account. This is a material operational event for a SPAC, as the extension directly affects the company's timeline to complete its stated business purpose and impacts the registrant's continued existence as a going concern if no business combination is completed by the extended deadline. While not a specific named event type, this is clearly an operational/strategic matter affecting the SPAC's core mission.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-09
Item 1.01
This disclosure describes entry into a Merger Agreement between two wholly owned subsidiaries of PMGC Holdings Inc. (AGA Precision Systems LLC merging into A&B Aerospace, Inc.), which constitutes a material acquisition or change of control event under Item 1.01. Although the merger involves only internal subsidiaries, the formalization of the merger agreement and its anticipated consummation represent a material corporate restructuring that would affect investor assessment of the company's organizational structure and operations.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-09
Item 2.01
T3 Defense acquired 60% of Project 35, an Israeli defense technology company, in exchange for 21,059,871 shares of common stock and a $1,250,000 promissory note, with an additional $2,500,000 investment obligation. This is a material acquisition disclosed under Item 2.01, involving significant equity dilution and cash commitment for a strategic defense-sector asset with established customer relationships and proprietary technology (HY-380 autonomous interceptor).
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-09
Item 5.02
The disclosure centers on the appointment of Derek Rush as a director and member of the audit committee on July 2, 2026, increasing the Board to seven members. While the section also mentions an indemnification agreement, the principal disclosed action is the appointment of a person to a board role. This is material to investors as it affects board composition and governance structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-09
Item 8.01
The disclosure describes a clinical trial milestone—preparation of a statistical analysis plan (SAP) for an interim analysis of a Phase 2/3 randomized, placebo-controlled trial of tafenoquine in severe babesiosis, with 23 of 33 planned patients enrolled as of the filing date. This is a material operational and regulatory development for a clinical-stage biopharmaceutical company, as it outlines the pathway toward potential FDA submission and a Commissioner's National Priority Review Voucher application by Q1 2028. The event is clearly operational/strategic (clinical development progress) rather than financial, governance, legal, or existential in nature, and does not fit a more specific category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-09
Item 1.01
Freedom Metals Acquisition Corp. consummated its initial public offering on July 9, 2026, issuing 27,500,000 units at $10.00 per unit for gross proceeds of $275 million, together with a concurrent private placement of 825,000 units to the Sponsor, Cohen, and CS at the same price for $8.25 million in gross proceeds.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-09
Item 5.02
On July 7, 2026, Bronwyn Barnes, Quinton Hennigh, Hugh Callaghan, and Michael Porter were appointed to the board of directors, with Barnes serving as Chairwoman and Porter chairing both the Audit and Compensation Committees.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-09
The 6-K discloses the appointment of two new independent directors effective July 9, 2026: Mr. King Fui Lee as an independent director and Audit Committee Chairman, and Mr. Ke Zhang as an independent director. While the filing also mentions the departure of two prior independent directors (Ms. Jie Jiao and Mr. Jingchuan Li), the principal disclosed action is the appointment of new board members with detailed biographical information, making this an exec_appointment event. Board composition changes affecting audit oversight are material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 94%
filed 2026-07-09
Item 1.01
CleanCore entered into a Contribution Agreement, LLC Agreement, and Master Platform Agreement on July 2, 2026, to form and capitalize a joint venture with HST Technologies for developing and operating data center facilities, with CleanCore contributing up to $100 million for a 99% capital interest and aggregate capital commitments contemplated up to $2 billion. The company announced the closing of its first data center project in partnership with HST Technologies, committing to fund an initial 200-megawatt West Texas data center campus with $100 million expected by Q1 2027, with potential expansion to 500+ megawatts by 2030, representing a material entry into the AI infrastructure business.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-07-09
Item 8.01
Osprey Acquisition Corp. III consummated an initial public offering of 30,015,000 units at $10.00 per unit on July 2, 2026, generating $300,150,000 in gross proceeds, plus a simultaneous private placement of 747,000 units for $7,470,000. This is a material capital-raising event involving the issuance of equity securities (Class A ordinary shares and warrants) to public and private investors. While this is technically a SPAC IPO rather than a traditional dilutive issuance to existing shareholders, the event represents a substantial unregistered or newly-registered equity issuance that materially affects the company's capitalization and is reportable under Item 8.01.
View raw filing on EDGAR →